Mauna Kea Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Mauna Kea TechnologiesDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 4.2% bzw. 14.9% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich zurückgehen wird.

Wichtige Informationen

-15.0%

Wachstumsrate der Gewinne

-15.0%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	14.0%
Wachstumsrate der Einnahmen	-4.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	05 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

What Mauna Kea Technologies SA's (EPA:ALMKT) 31% Share Price Gain Is Not Telling You

Jul 23

Mauna Kea Technologies SA's (EPA:ALMKT) Share Price Could Signal Some Risk

Mar 23

What Is Mauna Kea Technologies SA's (EPA:MKEA) Share Price Doing?

Jan 12

Mauna Kea Technologies (EPA:MKEA) Share Prices Have Dropped 70% In The Last Three Years

Nov 26

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:ALMKT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	9	-8	-7	-6	1
12/31/2025	8	-8	-4	-4	1
12/31/2024	7	-9	-6	0	1
12/31/2023	11	-4	-1	-1	N/A
9/30/2023	11	-3	-1	0	N/A
6/30/2023	12	-2	0	0	N/A
3/31/2023	10	-7	-4	-4	N/A
12/31/2022	8	-11	-9	-9	N/A
9/30/2022	8	-12	-10	-10	N/A
6/30/2022	8	-13	-11	-11	N/A
3/31/2022	8	-13	-11	-11	N/A
12/31/2021	9	-13	-11	-10	N/A
9/30/2021	8	-13	-11	-10	N/A
6/30/2021	8	-13	-11	-10	N/A
3/31/2021	8	-13	-10	-9	N/A
12/31/2020	7	-13	-9	-8	N/A
9/30/2020	7	-13	-10	-9	N/A
6/30/2020	7	-14	-12	-10	N/A
3/31/2020	8	-15	-12	-10	N/A
12/31/2019	9	-15	-12	-10	N/A
9/30/2019	9	-15	-11	-10	N/A
6/30/2019	9	-14	-11	-9	N/A
3/31/2019	9	-13	-12	-10	N/A
12/31/2018	8	-13	-12	-11	N/A
9/30/2018	8	-12	-11	-11	N/A
6/30/2018	7	-11	-11	-10	N/A
3/31/2018	8	-11	-11	-10	N/A
12/31/2017	8	-10	-10	-10	N/A
9/30/2017	8	-10	N/A	-9	N/A
6/30/2017	8	-11	N/A	-9	N/A
3/31/2017	9	-10	N/A	-8	N/A
12/31/2016	10	-10	N/A	-8	N/A
9/30/2016	10	-10	N/A	-8	N/A
6/30/2016	10	-10	N/A	-8	N/A
3/31/2016	10	-11	N/A	-10	N/A
12/31/2015	10	-13	N/A	-12	N/A
9/30/2015	11	-13	N/A	-12	N/A
6/30/2015	12	-14	N/A	-13	N/A
3/31/2015	12	-14	N/A	-13	N/A
12/31/2014	12	-14	N/A	-13	N/A
9/30/2014	12	-13	N/A	-12	N/A
6/30/2014	11	-12	N/A	-11	N/A
3/31/2014	11	-12	N/A	-10	N/A
12/31/2013	11	-12	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALMKT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ALMKT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ALMKT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ALMKTDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-4.2% pro Jahr).

Hohe Wachstumseinnahmen: ALMKTDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-4.2% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ALMKT in 3 Jahren voraussichtlich hoch sein wird

Mauna Kea Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 13%

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

No longer forecast to breakeven

No longer forecast to breakeven

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Recent updates

Mauna Kea Technologies Announces Positive Clinical Results in Lung Cancer Obtains with Cellvizio

New major risk - Share price stability

Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 30, 2024

What Mauna Kea Technologies SA's (EPA:ALMKT) 31% Share Price Gain Is Not Telling You

New minor risk - Share price stability

New minor risk - Share price stability

Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 02, 2024

Consensus EPS estimates fall by 13%

New major risk - Negative shareholders equity

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

New minor risk - Financial data availability

New minor risk - Share price stability

Mauna Kea Technologies SA's (EPA:ALMKT) Share Price Could Signal Some Risk

New minor risk - Share price stability

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Mauna Kea Technologies SA ADR - Sponsored to Be Deleted from OTC Equity

Mauna Kea Technologies SA announced that it expects to receive €6 million in funding from Telix Pharmaceuticals Limited

New minor risk - Share price stability

Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer

No longer forecast to breakeven

First half 2023 earnings released: EPS: €0.063 (vs €0.14 loss in 1H 2022)

New major risk - Revenue and earnings growth

Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone

No longer forecast to breakeven

Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer

Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio®

Consensus revenue estimates fall by 15%

Mauna Kea Technologies SA to Report First Half, 2023 Results on Sep 28, 2023

Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer

No longer forecast to breakeven

Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology

Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive Officer

Mauna Kea Technologies SA to Report First Half, 2022 Final Results on Oct 20, 2022

Mauna Kea Technologies SA to Report First Half, 2022 Results on Oct 20, 2022

Consensus forecasts updated

Price target decreased to €1.45

No longer forecast to breakeven

No longer forecast to breakeven

Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures

Mauna Kea Technologies SA Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial

Mauna Kea Technologies SA announced that it has received $12.8 million in funding from Lightspeed China Partners, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Shanghai Ivy Investment Holdings Co., Ltd.

First half 2021 earnings released

Price target decreased to €2.13

Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent

Consensus forecasts updated

Mauna Kea Technologies SA Provides Earnings Guidance for the Twelve Months Ending December 31, 2021

Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Full year 2020 earnings released

Mauna Kea Technologies: Cellvizio® Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification

What Is Mauna Kea Technologies SA's (EPA:MKEA) Share Price Doing?

Mauna Kea Technologies SA to Report Q2, 2021 Results on Jul 22, 2021

New 90-day high: €1.50

Mauna Kea Technologies Announces Board Changes

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announces Exclusive Scientific and Clinical Research Collaboration

New 90-day high: €1.42

Mauna Kea Technologies (EPA:MKEA) Share Prices Have Dropped 70% In The Last Three Years

New 90-day high: €1.34

New 90-day low: €1.05

New 90-day low - €1.14

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken